Gladius Capital Management LP I Teos Therapeutics, Inc. Transaction History

Gladius Capital Management LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$9.89 - $13.64 $2,492 - $3,437	252 Added 8.05%	3,383 $46,000
Q4 2023 Feb 07, 2024	BUY	$8.57 - $11.06 $8,792 - $11,347	1,026 Added 48.74%	3,131 $34,000
Q3 2023 Dec 18, 2023	BUY	$10.95 - $14.6 $8,902 - $11,869	813 Added 62.93%	2,105 $23,000
Q3 2023 Oct 10, 2023	BUY	$10.95 - $14.6 $8,902 - $11,869	813 Added 62.93%	2,105 $24,000
Q2 2023 Dec 18, 2023	SELL	$12.93 - $18.05 $10,512 - $14,674	-813 Reduced 38.62%	1,292 $17,000
Q2 2023 Aug 08, 2023	SELL	$12.93 - $18.05 $5,482 - $7,653	-424 Reduced 24.71%	1,292 $18,000
Q1 2023 Dec 18, 2023	SELL	$13.02 - $22.62 $5,064 - $8,799	-389 Reduced 18.48%	1,716 $23,000
Q1 2023 May 09, 2023	SELL	$13.02 - $22.62 $1,549 - $2,691	-119 Reduced 6.49%	1,716 $24,000
Q4 2022 Dec 18, 2023	SELL	$17.77 - $21.6 $4,797 - $5,832	-270 Reduced 12.83%	1,835 $35,000
Q4 2022 Feb 02, 2023	BUY	$17.77 - $21.6 $4,424 - $5,378	249 Added 15.7%	1,835 $36,000
Q3 2022 Nov 14, 2022	BUY	$18.6 - $27.25 $29,499 - $43,218	1,586 New	1,586 $31,000

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $257M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.